+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Global Duchenne Muscular Dystrophy Drugs Market by Drug Type (Casimersen, Deflazacort, Delandistrogene Moxeparvovec), Administration Method (Oral, Parental), End-Use - Forecast 2024-2030

  • PDF Icon

    Report

  • 198 Pages
  • June 2024
  • Region: Global
  • 360iResearch™
  • ID: 5967658
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Duchenne Muscular Dystrophy Drugs Market size was estimated at USD 1.57 billion in 2023, USD 1.70 billion in 2024, and is expected to grow at a CAGR of 8.61% to reach USD 2.80 billion by 2030.

Advancements in genetic research and breakthroughs in understanding the genetic basis of DMD are leading to more targeted and effective treatments, contributing to the market expansion. Higher global healthcare expenditure enables better treatment access for DMD, contributing to market growth. Funding and initiatives by governments and non-profit organizations boost research and development efforts, enhancing the market adoption of DMD drugs. Stringent regulatory requirements for drug approval and market introduction may delay access to innovative treatments, posing challenges in the market space. Moreover, ongoing advancements in gene editing technologies such as CRISPR/Cas9 and other gene-editing tools offer potential for curative treatments of Duchenne muscular dystrophy. The development of personalized medicine approaches tailored to individual genetic profiles may improve efficacy and minimize side effects, generating opportunities for market growth.

Regional Insights

In the Americas region, the United States and Canada are pivotal due to the strong presence of key players engaged in developing Duchenne Muscular Dystrophy (DMD) drugs. The Americas region is characterized by high consumer awareness, substantial investments in R&D, and favorable government policies. The United States holds a key position in developing breakthrough therapies and has several patents filed for innovative DMD treatments. Canada demonstrates strong governmental support and public-private partnerships, fostering growth in the market arena. The European Union countries are at the forefront regarding regulatory support for DMD drug development and have several initiatives supporting research and access to treatment. Patent activity is high in the EMEA region, with several countries contributing to discoveries. The Middle East region, although smaller in terms of market size, is witnessing increased investment and growing awareness. Africa faces challenges related to healthcare infrastructure and treatment access and shows potential for growth through international partnerships and investments. The Asia Pacific region, especially China, Japan, and India, has grown significantly in the DMD drugs market. The market growth in the APAC countries is attributed to increasing awareness, governmental initiatives, and improving healthcare infrastructure. Research and investment in APAC countries have been robust, with Japan leading in innovative therapies and patent filings. China and India are rapidly advancing in research and offering cost-effective treatments, significantly affecting market dynamics and customer purchasing behaviors.

Market Insights

Market Dynamics

  • The market dynamics represent an ever-changing landscape of the Duchenne Muscular Dystrophy Drugs Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers

  • Increasing prevalence of genetic diseases including Duchenne muscular dystrophy
  • Ongoing advancements in genetic research and breakthroughs in understanding the genetic basis of DMD

Market Restraints

  • High costs of DMD drug therapies

Market Opportunities

  • Advancements in gene-editing tools and gene editing technologies such as CRISPR/Cas9
  • Development of personalized medicine approaches tailored to individual genetic profiles

Market Challenges

  • Limited awareness and side affects associated with DMD drugs

Market Segmentation Analysis

  • Drug Type: Rising preference for casimersen for targeted treatment of Duchenne muscular dystrophy
  • End-Use: Increasing adoption of DMD drugs in ambulatory centers

Industry Insights

  • Market Disruption Analysis
  • Porter’s Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Duchenne Muscular Dystrophy Drugs Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Duchenne Muscular Dystrophy Drugs Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Agamree Receives FDA Approval as First “Dissociative Steroidal Anti-Inflammatory” to Treat Duchenne Muscular Dystrophy

The U.S. Food and Drug Administration has approved Agamree (vamorolone), a oral suspension treatment for Duchenne Muscular Dystrophy (DMD) in individuals aged two years and above. The Agamree is manufactured by Santhera Pharmaceuticals and commercialized in the U.S. by Catalyst Pharmaceuticals, stands as a novel therapeutic option, functioning through a unique mechanism that offers the potential benefits typical of corticosteroids with a modified, and potentially more favorable, activity profile.

FDA Approves a New Steroidal-Type Anti-Inflammatory Drug for Duchenne Muscular Dystrophy

ReveraGen BioPharma Inc. has received approval from the Food and Drug Administration for vamorolone, a pioneering treatment option for Duchenne muscular dystrophy (DMD) developed in collaboration with Children's National Hospital. With a distinct molecular composition that minimizes the adverse effects commonly associated with traditional corticosteroids, such as brittle bones and stunted growth, vamorolone offers a new hope for patients suffering with duchenne muscular dystrophy.

FDA Approves First Gene Therapy for Treatment of Certain Patients with Duchenne Muscular Dystrophy

The U.S. Food and Drug Administration (FDA) has approved Elevidys, a gene therapy for pediatric patients aged 4 to 5 with Duchenne muscular dystrophy (DMD) having a confirmed mutation in the DMD gene and is suitable for this treatment. This approval marks a significant advancement in addressing the urgent need for effective treatments against DMD, a severe genetic disorder characterized by progressive muscle degeneration. Developed through the FDA's Accelerated Approval pathway, elevidys introduces a shortened version of the dystrophin protein into the body, aiming to mitigate the muscular deterioration associated with the condition.

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Duchenne Muscular Dystrophy Drugs Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Duchenne Muscular Dystrophy Drugs Market, highlighting leading vendors and their innovative profiles. These include Anuh Pharma Limited, Arlak Biotech Pvt.Ltd., Aurigene Pharmaceutical Services Ltd., Bayer Pharmaceutical, Cipla Inc., Enomark, Glasier Wellness, Inc., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Leo Pharma, Lifecare Neuro Products Limited, Mankind Pharma Ltd., Merck & Co., Inc.,, MODASA Pharmaceuticals Pvt. Ltd., Novartis AG, Pfizer Inc., QndQ Derma, RayBiotech, Inc., Ronyd Healthcare Pvt Ltd., Sarepta Therapeutics, Inc., Sumitomo Corporation, Texas Pharmaceuticals Pvt. Ltd., Wallace Pharmaceuticals Pvt Ltd., Wellona Pharma, and Zuventus Healthcare Ltd..

Market Segmentation & Coverage

This research report categorizes the Duchenne Muscular Dystrophy Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

Drug Type

  • Casimersen
  • Deflazacort
  • Delandistrogene Moxeparvovec
  • Eteplirsen
  • Golodirsen
  • Viltolarsen

Administration Method

  • Oral
  • Parental

End-Use

  • Ambulatory Centres
  • Homecare Settings
  • Hospitals & Clinics

Region

Americas

  • Argentina
  • Brazil
  • Canada
  • Mexico
  • United States
  • California
  • Florida
  • Illinois
  • New York
  • Ohio
  • Pennsylvania
  • Texas

Asia-Pacific

  • Australia
  • China
  • India
  • Indonesia
  • Japan
  • Malaysia
  • Philippines
  • Singapore
  • South Korea
  • Taiwan
  • Thailand
  • Vietnam

Europe, Middle East & Africa

  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of genetic diseases including Duchenne muscular dystrophy
5.1.1.2. Ongoing advancements in genetic research and breakthroughs in understanding the genetic basis of DMD
5.1.2. Restraints
5.1.2.1. High costs of DMD drug therapies
5.1.3. Opportunities
5.1.3.1. Advancements in gene-editing tools and gene editing technologies such as CRISPR/Cas9
5.1.3.2. Development of personalized medicine approaches tailored to individual genetic profiles
5.1.4. Challenges
5.1.4.1. Limited awareness and side affects associated with DMD drugs
5.2. Market Segmentation Analysis
5.2.1. Drug Type: Rising preference for casimersen for targeted treatment of Duchenne muscular dystrophy
5.2.2. End-Use: Increasing adoption of DMD drugs in ambulatory centers
5.3. Market Disruption Analysis
5.4. Porter’s Five Forces Analysis
5.4.1. Threat of New Entrants
5.4.2. Threat of Substitutes
5.4.3. Bargaining Power of Customers
5.4.4. Bargaining Power of Suppliers
5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis
6. Duchenne Muscular Dystrophy Drugs Market, by Drug Type
6.1. Introduction
6.2. Casimersen
6.3. Deflazacort
6.4. Delandistrogene Moxeparvovec
6.5. Eteplirsen
6.6. Golodirsen
6.7. Viltolarsen
7. Duchenne Muscular Dystrophy Drugs Market, by Administration Method
7.1. Introduction
7.2. Oral
7.3. Parental
8. Duchenne Muscular Dystrophy Drugs Market, by End-Use
8.1. Introduction
8.2. Ambulatory Centres
8.3. Homecare Settings
8.4. Hospitals & Clinics
9. Americas Duchenne Muscular Dystrophy Drugs Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Duchenne Muscular Dystrophy Drugs Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Duchenne Muscular Dystrophy Drugs Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
12.3.1. Agamree Receives FDA Approval as First “Dissociative Steroidal Anti-Inflammatory” to Treat Duchenne Muscular Dystrophy
12.3.2. FDA Approves a New Steroidal-Type Anti-Inflammatory Drug for Duchenne Muscular Dystrophy
12.3.3. FDA Approves First Gene Therapy for Treatment of Certain Patients with Duchenne Muscular Dystrophy
12.4. Strategy Analysis & Recommendation
13. Competitive Portfolio
13.1. Key Company Profiles
13.2. Key Product Portfolio
List of Figures
FIGURE 1. DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET RESEARCH PROCESS
FIGURE 2. DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET DYNAMICS
FIGURE 7. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
FIGURE 8. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2023 VS 2030 (%)
FIGURE 10. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
FIGURE 12. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 22. DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, 2018-2023 (USD MILLION)
TABLE 4. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, 2024-2030 (USD MILLION)
TABLE 5. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
TABLE 6. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
TABLE 7. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 8. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 9. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY CASIMERSEN, BY REGION, 2018-2023 (USD MILLION)
TABLE 10. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY CASIMERSEN, BY REGION, 2024-2030 (USD MILLION)
TABLE 11. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DEFLAZACORT, BY REGION, 2018-2023 (USD MILLION)
TABLE 12. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DEFLAZACORT, BY REGION, 2024-2030 (USD MILLION)
TABLE 13. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DELANDISTROGENE MOXEPARVOVEC, BY REGION, 2018-2023 (USD MILLION)
TABLE 14. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DELANDISTROGENE MOXEPARVOVEC, BY REGION, 2024-2030 (USD MILLION)
TABLE 15. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ETEPLIRSEN, BY REGION, 2018-2023 (USD MILLION)
TABLE 16. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ETEPLIRSEN, BY REGION, 2024-2030 (USD MILLION)
TABLE 17. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GOLODIRSEN, BY REGION, 2018-2023 (USD MILLION)
TABLE 18. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GOLODIRSEN, BY REGION, 2024-2030 (USD MILLION)
TABLE 19. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY VILTOLARSEN, BY REGION, 2018-2023 (USD MILLION)
TABLE 20. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY VILTOLARSEN, BY REGION, 2024-2030 (USD MILLION)
TABLE 21. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
TABLE 22. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
TABLE 23. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2023 (USD MILLION)
TABLE 24. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2024-2030 (USD MILLION)
TABLE 25. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY PARENTAL, BY REGION, 2018-2023 (USD MILLION)
TABLE 26. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY PARENTAL, BY REGION, 2024-2030 (USD MILLION)
TABLE 27. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 28. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 29. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AMBULATORY CENTRES, BY REGION, 2018-2023 (USD MILLION)
TABLE 30. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AMBULATORY CENTRES, BY REGION, 2024-2030 (USD MILLION)
TABLE 31. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2023 (USD MILLION)
TABLE 32. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2024-2030 (USD MILLION)
TABLE 33. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2023 (USD MILLION)
TABLE 34. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2024-2030 (USD MILLION)
TABLE 35. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 36. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 37. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
TABLE 38. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
TABLE 39. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 40. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 41. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 42. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 43. ARGENTINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 44. ARGENTINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 45. ARGENTINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
TABLE 46. ARGENTINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
TABLE 47. ARGENTINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 48. ARGENTINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 49. BRAZIL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 50. BRAZIL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 51. BRAZIL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
TABLE 52. BRAZIL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
TABLE 53. BRAZIL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 54. BRAZIL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 55. CANADA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 56. CANADA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 57. CANADA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
TABLE 58. CANADA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
TABLE 59. CANADA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 60. CANADA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 61. MEXICO DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 62. MEXICO DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 63. MEXICO DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
TABLE 64. MEXICO DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
TABLE 65. MEXICO DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 66. MEXICO DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 67. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 68. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 69. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
TABLE 70. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
TABLE 71. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 72. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 73. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
TABLE 74. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
TABLE 75. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 76. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 77. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
TABLE 78. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
TABLE 79. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 80. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 81. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 82. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 83. AUSTRALIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 84. AUSTRALIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 85. AUSTRALIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
TABLE 86. AUSTRALIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
TABLE 87. AUSTRALIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 88. AUSTRALIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 89. CHINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 90. CHINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 91. CHINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
TABLE 92. CHINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
TABLE 93. CHINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 94. CHINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 95. INDIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 96. INDIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 97. INDIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
TABLE 98. INDIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
TABLE 99. INDIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 100. INDIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 101. INDONESIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 102. INDONESIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 103. INDONESIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
TABLE 104. INDONESIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
TABLE 105. INDONESIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 106. INDONESIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 107. JAPAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 108. JAPAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 109. JAPAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
TABLE 110. JAPAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
TABLE 111. JAPAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 112. JAPAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 113. MALAYSIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 114. MALAYSIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 115. MALAYSIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
TABLE 116. MALAYSIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
TABLE 117. MALAYSIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 118. MALAYSIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 119. PHILIPPINES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 120. PHILIPPINES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 121. PHILIPPINES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
TABLE 122. PHILIPPINES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
TABLE 123. PHILIPPINES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 124. PHILIPPINES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 125. SINGAPORE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 126. SINGAPORE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 127. SINGAPORE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
TABLE 128. SINGAPORE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
TABLE 129. SINGAPORE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 130. SINGAPORE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 131. SOUTH KOREA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 132. SOUTH KOREA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 133. SOUTH KOREA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
TABLE 134. SOUTH KOREA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
TABLE 135. SOUTH KOREA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 136. SOUTH KOREA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 137. TAIWAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 138. TAIWAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 139. TAIWAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
TABLE 140. TAIWAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
TABLE 141. TAIWAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 142. TAIWAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 143. THAILAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 144. THAILAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 145. THAILAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
TABLE 146. THAILAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
TABLE 147. THAILAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 148. THAILAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 149. VIETNAM DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 150. VIETNAM DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 151. VIETNAM DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
TABLE 152. VIETNAM DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
TABLE 153. VIETNAM DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 154. VIETNAM DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
TABLE 158. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
TABLE 159. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 160. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 161. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 162. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 163. DENMARK DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 164. DENMARK DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 165. DENMARK DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
TABLE 166. DENMARK DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
TABLE 167. DENMARK DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 168. DENMARK DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 169. EGYPT DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 170. EGYPT DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 171. EGYPT DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
TABLE 172. EGYPT DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
TABLE 173. EGYPT DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 174. EGYPT DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 175. FINLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 176. FINLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 177. FINLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
TABLE 178. FINLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
TABLE 179. FINLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 180. FINLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 181. FRANCE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 182. FRANCE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 183. FRANCE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
TABLE 184. FRANCE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
TABLE 185. FRANCE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 186. FRANCE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 187. GERMANY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 188. GERMANY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 189. GERMANY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
TABLE 190. GERMANY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
TABLE 191. GERMANY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 192. GERMANY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 193. ISRAEL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 194. ISRAEL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 195. ISRAEL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
TABLE 196. ISRAEL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
TABLE 197. ISRAEL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 198. ISRAEL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 199. ITALY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 200. ITALY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 201. ITALY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
TABLE 202. ITALY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
TABLE 203. ITALY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 204. ITALY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 205. NETHERLANDS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 206. NETHERLANDS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 207. NETHERLANDS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
TABLE 208. NETHERLANDS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
TABLE 209. NETHERLANDS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 210. NETHERLANDS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 211. NIGERIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 212. NIGERIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 213. NIGERIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
TABLE 214. NIGERIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
TABLE 215. NIGERIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 216. NIGERIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 217. NORWAY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 218. NORWAY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 219. NORWAY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
TABLE 220. NORWAY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
TABLE 221. NORWAY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 222. NORWAY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 223. POLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 224. POLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 225. POLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
TABLE 226. POLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
TABLE 227. POLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 228. POLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 229. QATAR DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 230. QATAR DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 231. QATAR DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
TABLE 232. QATAR DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
TABLE 233. QATAR DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 234. QATAR DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 235. RUSSIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 236. RUSSIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 237. RUSSIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
TABLE 238. RUSSIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
TABLE 239. RUSSIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 240. RUSSIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 241. SAUDI ARABIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 242. SAUDI ARABIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 243. SAUDI ARABIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
TABLE 244. SAUDI ARABIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
TABLE 245. SAUDI ARABIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 246. SAUDI ARABIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 247. SOUTH AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 248. SOUTH AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 249. SOUTH AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
TABLE 250. SOUTH AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
TABLE 251. SOUTH AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 252. SOUTH AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 253. SPAIN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 254. SPAIN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 255. SPAIN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
TABLE 256. SPAIN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
TABLE 257. SPAIN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 258. SPAIN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 259. SWEDEN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 260. SWEDEN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 261. SWEDEN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
TABLE 262. SWEDEN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
TABLE 263. SWEDEN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 264. SWEDEN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 265. SWITZERLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 266. SWITZERLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 267. SWITZERLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
TABLE 268. SWITZERLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
TABLE 269. SWITZERLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 270. SWITZERLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 271. TURKEY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 272. TURKEY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 273. TURKEY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
TABLE 274. TURKEY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
TABLE 275. TURKEY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 276. TURKEY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 277. UNITED ARAB EMIRATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 278. UNITED ARAB EMIRATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 279. UNITED ARAB EMIRATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
TABLE 280. UNITED ARAB EMIRATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
TABLE 281. UNITED ARAB EMIRATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 282. UNITED ARAB EMIRATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 283. UNITED KINGDOM DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 284. UNITED KINGDOM DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 285. UNITED KINGDOM DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
TABLE 286. UNITED KINGDOM DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
TABLE 287. UNITED KINGDOM DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 288. UNITED KINGDOM DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 289. DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 290. DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

  • Anuh Pharma Limited
  • Arlak Biotech Pvt.Ltd.
  • Aurigene Pharmaceutical Services Ltd.
  • Bayer Pharmaceutical
  • Cipla Inc.
  • Enomark
  • Glasier Wellness, Inc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Leo Pharma
  • Lifecare Neuro Products Limited
  • Mankind Pharma Ltd.
  • Merck & Co., Inc.,
  • MODASA Pharmaceuticals Pvt. Ltd.
  • Novartis AG
  • Pfizer Inc.
  • QndQ Derma
  • RayBiotech, Inc.
  • Ronyd Healthcare Pvt Ltd.
  • Sarepta Therapeutics, Inc.
  • Sumitomo Corporation
  • Texas Pharmaceuticals Pvt. Ltd.
  • Wallace Pharmaceuticals Pvt Ltd.
  • Wellona Pharma
  • Zuventus Healthcare Ltd.

Methodology

Loading
LOADING...

Table Information